- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02452983
Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (SS1)
May 31, 2022 updated by: Gustavo Rivero
SS1: Pilot Study of Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (MDS)
This study will investigate the effects of sertraline in people with low-risk myelodysplastic syndrome (MDS).
It is hoped that sertraline will decrease disease progression and reduce the need for blood transfusions.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This pilot study investigates clinical benefit of four 28-day cycles of sertraline in low-risk MDS patients.
Participants will receive 100mg of oral sertraline daily.
The study will also evaluate potential associated biological mechanisms of action.
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
Houston, Texas, United States, 77030
- Michael E. DeBakey VA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of Very Low or Low risk MDS defined by IPSS-R confirmed by a bone marrow aspirate and biopsy (Blast count must be < 20%)
- Hemoglobin < 11 g/dL, or transfusion dependency.
- Platelet count <100,000/mm3
- Absolute Neutrophil Count (ANC) < 1000/mm3
- Life expectancy of 12 months or greater
- ECOG Performance status of 0 - 3
- Age ≥ 18 years
- Willing to use medically acceptable methods of birth control during the study and for 28 days after discontinuing study treatment
- All subjects must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- Both men and women and members of all races and ethnic groups
Exclusion Criteria:
- Previous exposure to 5-AC (azacitidine) or decitabine
- Use of antidepressants such as sertraline within 6 weeks OR use of paroxetine, fluoxetine, or citalopram within 3 months prior to registration
- Active cases (within past 12 months) of depressive disorder, manic episodes, and/or anxiety requiring active treatment with an SSRI. Patients being treated with an SSRI for non-psychiatric indication are allowed, and should go through the appropriate washout.
- Previous or concurrent malignancy, except treated basal cell or squamous cell cancer of skin, treated in situ cervical cancer, treated lobular or ductal carcinoma in situ in one breast, or any other cancer for which the patient has been disease-free for at least 5 years
- Actively receiving chemo-immunotherapy
- Evidence of active infection
- Treatment with steroids or immunosuppressive therapy such as cyclosporine, tacrolimus, anti-thymocyte globulin (ATG) within 6 months of registration
- Platelet transfusion within 8 weeks of registration.
- Platelet count < 20,000/mm3 within 14 days of registration.
- Active treatment with growth factors such erythropoietin stimulating agent (ESA), granulocyte colony-stimulating factor (GCSF), thrombopoietin stimulating factor within 8 weeks of registration
- Treatment with an investigational agent within 4 weeks of registration
- History of autoimmune disease including rheumatoid arthritis, systemic lupus and sarcoidosis
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sertraline
- Known history of splenomegaly
- Pregnant or nursing women are excluded from this study because Sertraline is a Class C agent with the potential for teratogenic or abortive effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sertraline, breast feeding should be discontinued.
- HIV: Given high risk for Immune thrombocytopenic purpura, HIV associated neutropenia and combination antiretroviral therapy, patients with known HIV are excluded because of the potential for pharmacokinetic interactions with sertraline.
- Any condition or illness that, in the Investigator's opinion, would place the subject at unacceptable risk if he/she were to participate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sertraline
Sertraline tablets 100mg daily for 4 (28-day) cycles
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematological Improvement - minor (HI-minor)
Time Frame: 16 weeks
|
Improvement in erythroid, neutrophil or platelet
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HI-minor response rate
Time Frame: 4 weeks
|
HI-minor response rate Cycle 1
|
4 weeks
|
HI-minor response rate
Time Frame: 8 weeks
|
HI-minor response rate Cycle 2
|
8 weeks
|
HI-minor response rate
Time Frame: 12 weeks
|
HI-minor response rate Cycle 3
|
12 weeks
|
HI-minor response rate
Time Frame: 16 weeks
|
HI-minor response rate Cycle 4
|
16 weeks
|
Individual rates of HI minor measurements: erythroid, neutrophil and platelet
Time Frame: 4 weeks
|
Individual rates of HI minor measurements at Cycle 1: erythroid, neutrophil and platelet
|
4 weeks
|
Individual rates of HI minor measurements: erythroid, neutrophil and platelet
Time Frame: 8 weeks
|
Individual rates of HI minor measurements at Cycle 2: erythroid, neutrophil and platelet
|
8 weeks
|
Individual rates of HI minor measurements: erythroid, neutrophil and platelet
Time Frame: 12 weeks
|
Individual rates of HI minor measurements at Cycle 3: erythroid, neutrophil and platelet
|
12 weeks
|
Individual rates of HI minor measurements: erythroid, neutrophil and platelet
Time Frame: 16 weeks
|
Individual rates of HI minor measurements at Cycle 4: erythroid, neutrophil and platelet
|
16 weeks
|
Hematological Improvement - major (HI-major) response rate
Time Frame: 4 weeks
|
HI-major response rate at Cycle 1
|
4 weeks
|
Hematological Improvement - major (HI-major) response rate
Time Frame: 8 weeks
|
HI-major response rate at Cycle 2
|
8 weeks
|
Hematological Improvement - major (HI-major) response rate
Time Frame: 12 weeks
|
HI-major response rate at Cycle 3
|
12 weeks
|
Hematological Improvement - major (HI-major) response rate
Time Frame: 16 weeks
|
HI-major response rate at Cycle 4
|
16 weeks
|
Individual rates of HI major measurements: erythroid, neutrophil and platelet
Time Frame: 4 weeks
|
Individual rates of HI major measurements at Cycle 1: erythroid, neutrophil and platelet
|
4 weeks
|
Individual rates of HI major measurements: erythroid, neutrophil and platelet
Time Frame: 8 weeks
|
Individual rates of HI major measurements at Cycle 2: erythroid, neutrophil and platelet
|
8 weeks
|
Individual rates of HI major measurements: erythroid, neutrophil and platelet
Time Frame: 12 weeks
|
Individual rates of HI major measurements at Cycle 3: erythroid, neutrophil and platelet
|
12 weeks
|
Individual rates of HI major measurements: erythroid, neutrophil and platelet
Time Frame: 16 weeks
|
Individual rates of HI major measurements at Cycle 4: erythroid, neutrophil and platelet
|
16 weeks
|
Serum cytokine level modifications
Time Frame: 4 weeks
|
Measured as the difference between Week 4 and pre-treatment levels
|
4 weeks
|
Serum cytokine level modifications
Time Frame: 8 weeks
|
Measured as the difference between Week 8 and pre-treatment levels
|
8 weeks
|
Serum cytokine level modifications
Time Frame: 12 weeks
|
Measured as the difference between Week 12 and pre-treatment levels
|
12 weeks
|
Serum cytokine level modifications
Time Frame: 16 weeks
|
Measured as the difference between Week 16 and pre-treatment levels
|
16 weeks
|
Changes in the Gene Expression Profile
Time Frame: Between Baseline and Day 14
|
Measured as the difference between Day 14 and Baseline
|
Between Baseline and Day 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Gustavo A Rivero, MD, Baylor College of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2015
Primary Completion (Actual)
November 1, 2020
Study Completion (Actual)
November 1, 2020
Study Registration Dates
First Submitted
May 21, 2015
First Submitted That Met QC Criteria
May 22, 2015
First Posted (Estimate)
May 25, 2015
Study Record Updates
Last Update Posted (Actual)
June 2, 2022
Last Update Submitted That Met QC Criteria
May 31, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Syndrome
- Myelodysplastic Syndromes
- Preleukemia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Sertraline
Other Study ID Numbers
- H-36160
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on Sertraline
-
Beijing HuiLongGuan HospitalCompleted
-
Maastricht University Medical CenterPfizerCompletedDepression | Chest Pain | Panic AttacksNetherlands
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
University of Sao PauloCompletedObsessive-Compulsive DisorderBrazil
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI)CompletedDepression | Myocardial Infarction | Heart Diseases | Cardiovascular Diseases | Angina, UnstableUnited States
-
TakedaCompletedCrohn's Disease | Ulcerative ColitisBelgium, United States, Korea, Republic of, Malaysia, Canada, Israel, Australia, Hungary, Czechia, Germany
-
University of PittsburghCompleted
-
Su RuiUnknown
-
Rhode Island HospitalStanford University; University of Cincinnati; American Epilepsy Society; Epilepsy...CompletedDepression | Stress Disorders, Post-Traumatic | Dissociative Disorders | Conversion Disorder | Convulsion, Non-EpilepticUnited States
-
TakedaCompleted